CAR T-Cell Therapy in India
Also known as Chimeric antigen receptor T-cell therapy, NexCAR19 therapy, CAR-T for leukemia, CAR-T for lymphoma, cellular immunotherapy, living drug cancer therapy
The short answer
CAR T-cell therapy in India costs between $45,000 and $85,000 using India's own NexCAR19 therapy, against $400,000 or more for equivalent imported CAR-T products in the US. It is a personalised cancer treatment where a patient's own immune cells are collected, genetically engineered to attack their specific cancer, and reinfused, currently approved for certain relapsed blood cancers.
About CAR T-Cell Therapy
CAR T-cell therapy is a form of personalised cellular immunotherapy in which a patient's own T-cells, a type of immune cell, are collected, genetically modified in a laboratory to recognise a specific marker on their cancer cells, and then reinfused back into the body. Once reinfused, these engineered cells multiply and seek out and destroy cancer cells carrying that marker. It is sometimes called a "living drug" because the treatment is made individually from each patient's own cells rather than manufactured as a standard drug.
India's own CAR-T therapy: NexCAR19
NexCAR19 is India's first indigenously developed CAR T-cell therapy, created by ImmunoACT, a company incubated at IIT Bombay, in partnership with Tata Memorial Centre. Approved by India's drug regulator in 2023, it targets CD19, a marker found on certain B-cell blood cancers, and costs a fraction of equivalent imported CAR-T products used in the US and Europe, without a different underlying approach or clinical rationale.
Who is currently eligible
NexCAR19 is currently approved for specific relapsed or treatment-resistant blood cancers: B-cell acute lymphoblastic leukaemia (ALL) in patients aged 15 and above, and certain types of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), in patients who have already tried at least two prior lines of treatment without lasting success. It is not currently a first-line treatment, nor is it approved for solid tumours, an area still being researched globally. Your haemato-oncologist confirms eligibility based on your specific diagnosis, cancer subtype and treatment history.
Why monitoring matters so much
The most serious known side effect of CAR T-cell therapy is cytokine release syndrome (CRS), an intense immune reaction that can occur as the engineered cells become active in the body, along with a risk of neurological side effects. Because of this, patients are closely monitored, usually with an inpatient stay including ICU-level monitoring capability, for a defined period after infusion. This monitoring is a core part of the treatment, not an optional add-on, and is a major reason the process takes weeks rather than days.
Why patients choose India for this
NexCAR19 was developed specifically to bring CAR-T treatment within reach at a fraction of the roughly $400,000+ cost of equivalent imported products used in Western countries.
NexCAR19 was created through a partnership between IIT Bombay and Tata Memorial Centre, two of India's leading scientific and cancer research institutions, and is now offered at an expanding network of hospitals across the country.
Our partner hospitals include centres with real CAR-T treatment volume and established protocols for cell collection, monitoring and managing side effects such as cytokine release syndrome.
Because safe CAR-T recovery depends on the ability to manage cytokine release syndrome quickly if it occurs, partner hospitals build ICU-level monitoring capability into the admission from day one.
CAR T-Cell Therapy cost
| Country | Indicative cost |
|---|---|
| India — with Nobel Medi Assistance | $45,000 – $85,000 |
| United States | $400,000 - $500,000+ |
| United Kingdom | $300,000 - $450,000 |
| Germany / Europe | $300,000 - $400,000 |
| UAE / Middle East | $250,000 - $400,000 |
Figures are indicative for international patients and depend on the hospital, the surgeon and your reports. Your exact cost is confirmed in writing after a specialist review — free, and with no obligation.
What the estimate covers
Included
- Haemato-oncologist consultation and treatment planning
- T-cell collection (apheresis) procedure
- NexCAR19 CAR-T cell manufacturing
- Lymphodepletion chemotherapy before infusion
- CAR-T cell infusion
- Inpatient monitoring, including ICU-level capability, for cytokine release syndrome
- Routine medicines during the monitoring period
Not included
- Diagnostic workup and confirmation of eligibility done before arrival in India
- Prior lines of treatment required before CAR-T eligibility, if not already completed
- Flights, visa and travel insurance
- Accommodation for the full treatment period (4-6 weeks)
- Extended ICU care beyond the standard monitoring period, if cytokine release syndrome is severe
- Long-term follow-up visits and response assessments after returning home
How CAR T-Cell Therapy is done
- Consultation and eligibility reviewA haemato-oncologist reviews your diagnosis, cancer subtype and prior treatment history remotely to confirm whether you meet current eligibility criteria for CAR-T therapy.
- On arrival, blood tests, imaging and organ function tests confirm you are fit for the procedure and finalise the treatment plan.
- T-cell collection (apheresis)Blood is drawn through a vein, passed through a machine that separates out your T-cells, and the remaining blood components are returned to you; this takes a few hours.
- Cell manufacturingYour T-cells are sent for genetic engineering into CAR-T cells, a laboratory process that takes roughly 2-4 weeks.
- Lymphodepletion chemotherapyA short course of chemotherapy is given just before infusion to prepare your body to receive the engineered cells.
- CAR-T cell infusionThe engineered cells are reinfused through an IV line, a procedure that itself takes under an hour.
- Inpatient monitoringYou are monitored closely, with ICU-level capability available, for signs of cytokine release syndrome or neurological side effects over the following 1-2 weeks before discharge.
Recovery and what to expect
- First 1-2 weeks after infusionClosely monitored as an inpatient for cytokine release syndrome and neurological side effects, the period when these are most likely to occur.
- 2-3 weeks after infusionIf no significant complications have occurred, discharge follows, with continued close outpatient monitoring while still in India.
- Day 28 assessmentA formal response assessment, often including a bone marrow biopsy or imaging, evaluates how the cancer has responded to treatment.
- 4-6 weeks after infusionMost patients are cleared to travel home if recovery and initial response assessment are satisfactory.
- OngoingLong-term monitoring for response durability and any delayed effects continues for months, coordinated with your home haematology-oncology team.
Specialists who perform this
Dr Surender Kumar Dabas
Oncology / Robotic Cancer Surgery 👑 22+ years
Dr Ruquaya Ahmad Mir
Oncology / Surgical Oncology 👑 20+ years
Dr Vedant Kabra
Oncology / Surgical Oncology 👑 28+ years
Dr. Jalaj Baxi
Surgical Oncology 👑 27+ years
Dr. Deepak Jha
Breast Surgery / Surgical Oncology 👑 15++ years
Dr. Piyush Kumar Agarwal
Surgical Oncology 👑 24+ years
Dr. Deepak Sarin
ENT – Head & Neck Oncology Surgery 👑 30+ years
Dr. Vinod Raina
Medical Oncology 👑 42+ yearsWhere it is done
Frequently asked questions
Am I eligible for CAR T-cell therapy?
Is CAR-T available for solid tumours?
What is cytokine release syndrome?
How long does the whole process take?
How effective is CAR-T therapy?
Can I stay with a family member during treatment?
Why is CAR-T therapy so much cheaper in India than in my home country?
What would your CAR T-Cell Therapy cost?
Send your reports and a senior specialist sends back a written plan with costs within 24 hours. Free, with no obligation.